Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Václav Šmíd"'
Autor:
Václav Šmíd, Karel Dvořák, Petr Šedivý, Vít Kosek, Martin Leníček, Monika Dezortová, Jana Hajšlová, Milan Hájek, Libor Vítek, Kamila Bechyňská, Radan Brůha
Publikováno v:
Hepatology Communications, Vol 6, Iss 6, Pp 1336-1349 (2022)
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. n‐3 polyunsaturated fatty acids (n‐3‐PUFAs) have been reported to ameliorate the progression of NAFLD in experimental studies; however, clinical trials have yiel
Externí odkaz:
https://doaj.org/article/ac9851f6a8084a2786db1dc1a9a79346
Autor:
Martin Leníček, Václav Šmíd, Petr Pajer, Anna Nazarova, Karel Dvořák, Iva Subhanová, Radan Brůha, Libor Vítek
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
Abstract The patatin-like phospholipase domain containing 3 (PNPLA3) gene (viz. its I148M variant) is one of the key players in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). We have identified a novel insertion/deletion variant of 111
Externí odkaz:
https://doaj.org/article/5581a4fd50f34deaa352f9233e04797f
Autor:
Jaromír Petrtýl, Karel Dvořák, Jan Stříteský, Martin Leníček, Alena Jirásková, Václav Šmíd, Martin Haluzík, Radan Brůha, Libor Vítek
Publikováno v:
Antioxidants, Vol 10, Iss 12, p 2000 (2021)
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide. The aim of our study was to assess the role of bilirubin, and the heme oxygenase 1 (HMOX1) and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter
Externí odkaz:
https://doaj.org/article/033bb2e8916540f4bfa7ade8cf3b9de0
Autor:
Kateřina Žížalová, Barbora Nováková, Marek Vecka, Jaromír Petrtýl, Věra Lánská, Květa Pelinková, Václav Šmíd, Radan Brůha, Libor Vítek, Martin Leníček
Publikováno v:
Liver International. 43:888-895
Severity of portal hypertension is usually quantified by measuring the hepatic venous pressure gradient (HVPG). However, due to its invasiveness, alternative markers are being sought. Bile acids (BA), being synthesized, metabolized, and transported b
Autor:
Václav, Šmíd
Publikováno v:
Casopis lekaru ceskych. 161(2)
Liver function tests are among the most determined biochemical parameters, and it is essential that their interpretation is always performed correctly. The presence of liver disease is indicated not only by the well-known basic panel of liver functio
Autor:
Karel, Dvořák, Václav, Šmíd
Publikováno v:
Casopis lekaru ceskych. 161(2)
Finding an effective treatment of non-alcoholic fatty liver disease (NAFLD) remains one of main challenges in hepatological research for the 21st century, since there is no such a treatment yet. Lifestyle modifications leading to weight reduction are
Autor:
Šimon, Dostál, Václav, Šmíd
Publikováno v:
Casopis lekaru ceskych. 161(2)
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in developed countries, where it affects up to a quarter of the population. The groups at most risk are diabetics, obese and patients with dyslipidemia, i. e
Autor:
Václav, Šmíd
Publikováno v:
Vnitřní lékařství. 66:e36-e41
Liver fibrosis is the excessive deposition of extracellular matrix in liver tissue resulting in structural and functional liver changes. The basis for these changes is the imbalance between fibrogenesis and fibrolysis, which arises in response to chr
Autor:
Vítek, Jaromír Petrtýl, Karel Dvořák, Jan Stříteský, Martin Leníček, Alena Jirásková, Václav Šmíd, Martin Haluzík, Radan Brůha, Libor
Publikováno v:
Antioxidants; Volume 10; Issue 12; Pages: 2000
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide. The aim of our study was to assess the role of bilirubin, and the heme oxygenase 1 (HMOX1) and bilirubin UDP-glucuronosyl transferase (UGT1A1) promoter
Non-alcoholic fatty liver disease - how to effectively fight the nowadays most common liver disease?
Autor:
Václav, Šmíd
Publikováno v:
Casopis lekaru ceskych. 160(2-3)
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease nowadays. It is referred to as liver manifestation of metabolic syndrome. Given the growing incidence of diabetes and obesity, we can confidently say that we will be,